As eGFR decreased, risks for 30-day hospital readmission or death increased for patients with chronic kidney disease, according to study data published in Clinical Journal of the American Society of ...

Trials of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, are documenting its direct kidney effects and broad benefits for diabetic kidney disease.

Having a cystatin C-based eGFR value at least 30% lower than creatinine-based eGFR is associated with increased risks of early death, cardiovascular events, and kidney failure requiring replacement ...

Compared with placebo, semaglutide lowered risks for adverse kidney outcomes and mortality across the chronic kidney disease spectrum, according to study data published in Clinical Journal of the ...

For many people with IgA nephropathy (IgAN), a condition in which immunoglobulin A (IgA) antibodies accumulate in the kidneys and trigger inflammation, kidney function stays stable for many years. For ...

A race-free revision of the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation for calculating estimated glomerular filtration rate (eGFR), introduced in September 2021, has rapidly ...

This study has three key findings. First, although metformin use has increased in the past decade for treatment of the general population with type 2 diabetes, it remains underused among individuals ...

Transdermal GFR System (TGFR) is a first-in-kind product for point of care assessment of kidney function in patients with normal or impaired renal function The transdermal GFR (tGFR) methodology has ...